PIK3CD (PI3 Kinase p110 Delta) Drug Discovery Landscape & Assay Solutions

  • By admin
  • 03 Aug 2026
  • Comments

Market Intelligence, Clinical Progress, and High-Purity Reagents for Hematologic Malignancy & Immuno-Oncology Development.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for PIK3CD drug discovery. Select your modality below:

Component / Network Product Description Product Link
Antigen PIK3CD Recombinant Kinase Protein (WT & Drug-Resistance Mutants). High purity (>95%), Endotoxin <1 EU/µg. ATP-binding verified by thermal shift. Sequence Verified. View PIK3CD Products
Gene Delivery PIK3CD Promise-ORF / Lentivirus Particles (WT and E1021K mutant). Full-length ORF for stable cell line construction. View PIK3CD Products
Benchmark Ab Anti-PIK3CD Recombinant Antibody. Research-grade positive control for Western Blot, IP, and IHC. View PIK3CD Products
Validator PIK3CD siRNA Set. For isoform-specific knockdown and pathway validation. View PIK3CD Products
Isoform Control PIK3CA (p110α) Recombinant Protein. For selectivity counter-screening (avoid metabolic toxicity). View PIK3CA Products
Isoform Control PIK3CB (p110β) Recombinant Protein. For selectivity counter-screening. View PIK3CB Products
Isoform Control PIK3CG (p110γ) Recombinant Protein. For immune modulation selectivity. View PIK3CG Products
Pathway Partner BTK Recombinant Protein. Upstream kinase in BCR signaling pathway. View BTK Products

Note: all recombinant proteins are expressed in HEK293 cells for true head-to-head comparison and are sequence verified.

Critical Assay Challenges & TarMart Advantage

Critical Assay Challenge The TarMart Advantage (Technical Spec)
Isoform Selectivity (vs p110α/β/γ) High-purity PI3K family panel (Alpha, Beta, Gamma, Delta) available with >95% purity and Theoretical MW strictly verified by mass spec. Identical expression systems (HEK293) for true head-to-head comparison.
Drug Resistance Profiling WT + Mutant recombinant proteins (E1021K, C420R, N334K) covering activation-loop and drug-binding hotspots. Endotoxin Controlled (<1 EU/µg).
APDS Mutation Targeting Clinically relevant mutant proteins (e.g., E1021K) available, sequence verified for precision medicine assays.
Cellular Context / Target Validation Lentivirus pre-made particles for stable expression in suspension cell lines (Raji, Jurkat).
Assay Specificity & False Positives Validated siRNA included for genetic knockdown confirmation and specificity checks.
Lack of Expression Controls Recombinant benchmark antibodies included for precise western blot and IHC profiling.

Live PIK3CD R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The race for PI3Kδ therapeutics is intensifying. First-generation PI3Kδ-selective inhibitors (e.g., Idelalisib) faced challenges including hepatotoxicity, colitis, and immune-mediated adverse events, leading to black-box warnings. Consequently, the field is shifting toward next-generation strategies:

  • Ultra-selective Small Molecules: Novel δ-selective inhibitors (e.g., Parsaclisib, Linperlisib) aim for >100-fold selectivity over other PI3K isoforms to reduce off-target toxicity.
  • Allosteric Inhibitors: Targeting non-ATP binding pockets to overcome resistance mutations in the ATP-binding site (e.g., E1021K, C420R). Requires conformation-stable WT vs mutant proteins for biochemical assay development.
  • Targeted Protein Degraders (PROTACs): Emerging modality to achieve complete degradation of PIK3CD, potentially overcoming both catalytic and scaffold functions. Early preclinical stage.
  • Inhaled Formulations: For respiratory indications like asthma and COPD (GSK, Novartis), requiring high-concentration formulation stability and rapid systemic clearance.
  • Combination Therapies: PI3Kδ inhibitors in combination with BTK inhibitors (e.g., Ibrutinib) or BCL-2 inhibitors (Venetoclax) are being explored to bypass resistance and enhance efficacy in relapsed/refractory CLL.

The next wave of R&D is focusing on mutant-selective strategies, isoform selectivity, and targeted combinations that maintain a stringent safety profile.

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
δ-Selective Small Molecule Gilead (Idelalisib), Bayer (Copanlisib), Verastem/Incyte (Duvelisib), Incyte (Parsaclisib), Innovent CLL, FL, DLBCL Isoform Selectivity Panel (Need PIK3CA/CB/CD/CG proteins with matched specs)
Allosteric Inhibitor Various biotechs Hematologic malignancies Non-ATP competitive binding assay (Need conformation-stable WT vs mutant proteins)
Resistance Mutant Inhibitors Academic/Early biotech Relapsed/Refractory E1021K, C420R mutant proteins for IC50 profiling
Inhaled Small Molecule GSK, Novartis Asthma, COPD High-concentration formulation stability (Need endotoxin-controlled proteins)
PROTAC / Degrader Biotech innovators Refractory lymphoma Degradation assays (Need HEK293 expressed full-length proteins)
Combination Therapy AstraZeneca, Gilead Relapsed/Refractory CLL, FL Pathway synergy (Need related targets like BTK, SYK, AKT)